CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-01 | Wysenski Nancy Director | Grant or award | +114 | 22,870 | ||
| 2024-07-01 | WIERENGA WENDALL Director | Grant or award | +114 | 24,441 | ||
| 2024-07-01 | Kaye Edward M. MD Director | Grant or award | +228 | 25,145 | ||
| 2024-07-01 | HENDERSON JOHN T Director | Grant or award | +388 | 38,058 | ||
| 2024-07-01 | Harrington Robert Arthur Director | Grant or award 10b5-1 | +228 | 15,769 | ||
| 2024-07-01 | PARSHALL B LYNNE Director | Option exercise 10b5-1 | +5,000 | $10.68 | $53K | 25,600 |
| 2024-07-01 | PARSHALL B LYNNE Director | Sale 10b5-1 | −5,000 | $54.22 | $271K | 20,600 |
| 2024-07-01 | PARSHALL B LYNNE Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 5,000 | ||
| 2024-07-01 | Blum Robert I President & CEO | Sale 10b5-1 | −11,500 | $54.05 | $622K | 405,145 |
| 2024-06-25 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $53.74 | $107K | 133,004 |
| 2024-06-25 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 138,304 |
| 2024-06-25 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $53.71 | $285K | 133,004 |
| 2024-06-25 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 63,600 | ||
| 2024-06-17 | PARSHALL B LYNNE Director | Option exercise 10b5-1 | +5,000 | $10.68 | $53K | 25,600 |
| 2024-06-17 | PARSHALL B LYNNE Director | Sale 10b5-1 | −5,000 | $52.55 | $263K | 20,600 |
| 2024-06-17 | PARSHALL B LYNNE Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 10,000 | ||
| 2024-06-17 | Blum Robert I President & CEO | Sale 10b5-1 | −11,551 | $52.60 | $608K | 427,594 |
| 2024-06-17 | Blum Robert I President & CEO | Sale 10b5-1 | −10,949 | $52.59 | $576K | 416,645 |
| 2024-06-11 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,422 | $7.96 | $43K | 142,792 |
| 2024-06-11 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,422 | $53.05 | $288K | 137,370 |
Page 31 of 33 · 660 trades